TLRY, US88688T2096

Tilray approves Portugal testing while Tilray Brands stock costs EUR 2.76

Published on 10/15/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Tilray Brands stock costs EUR 2.76 on October 15, 2026. First-quarter revenue rose 23.00 percent to USD 257.15 million.

Regulatory milestone and operating scale

Tilray Medical received INFARMED approval for two in-house testing categories on October 13, 2026.
First-quarter revenue reached USD 257.15 million, up 23.00 percent year over year, on October 8, 2026.
Tilray Brands stock was trading at EUR 2.76 at 1:07 p.m. CEST at Lang & Schwarz on October 15, 2026.

TLRY, US88688T2096, Illustration mit AI erstellt.

Tilray Brands (ISIN US88688T2096) was trading at EUR 2.76 at Lang & Schwarz on October 15, 2026, as the company advanced its European medical-cannabis platform. On October 13, 2026, Tilray reported that Portugal's INFARMED had approved its Cantanhede facility to conduct microbiological and chemical and physical testing in-house.

Portugal approval changes the process

The authorization gives Tilray Medical greater control over quality testing within its European Union good manufacturing practice platform. The company said the move can reduce reliance on outside laboratories, shorten testing timelines and support faster product release across regulated international markets.

The approval also strengthens the strategic role of the Portugal site, which combines cultivation, production and testing capabilities. Tilray Medical said its international supply network serves markets including Germany, the United Kingdom, Poland and Italy, linking the regulatory milestone to a broader European distribution strategy.

What does the quarter show?

Tilray's first fiscal quarter of 2027, ended August 31, 2026, delivered USD 257.15 million in net revenue, up 23.00 percent from USD 209.50 million a year earlier. According to Yahoo Finance, gross profit rose 35.00 percent to USD 77.51 million, while gross margin expanded to 30.00 percent from 27.00 percent.

Beverage revenue was the main growth engine at USD 101.50 million, up 82.00 percent year over year, while cannabis revenue declined to USD 56.10 million from USD 64.50 million. The quarter still produced a USD 40.03 million net loss, and adjusted earnings before interest, taxes, depreciation and amortization fell to USD 9.21 million from USD 10.18 million. Tilray reaffirmed fiscal 2027 adjusted earnings before interest, taxes, depreciation and amortization guidance of USD 68 million to USD 75 million.

Stock price stays the market anchor

For investors, the latest operating picture is mixed: beverage scale and higher gross margin contrast with continuing losses and weaker cannabis revenue. The October 13 regulatory milestone therefore adds operational substance to Tilray's European growth strategy, while the first-quarter figures keep profitability and execution central to the stock story.

Tilray Brands stock was trading at EUR 2.76 at Lang & Schwarz on October 15, 2026 at 1:07 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Tilray Brands stock.